Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Gallagher NeilOwnership Type:Direct OwnershipSecurities:No securities are beneficially ownedNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Gallagher NeilOwnership Type:Direct OwnershipSecurities:No securities are beneficially ownedNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Feb 09, 2024 (filed on Feb 09, 2024)Insider Name:Cesano AlessandraOwnership Type:Direct OwnershipSecurities:No securities are beneficially ownedNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Feb 09, 2024 (filed on Feb 09, 2024)Insider Name:Cesano AlessandraOwnership Type:Direct OwnershipSecurities:No securities are beneficially ownedNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Feb 08, 2024 (filed on Feb 09, 2024)Insider Name:Cesano AlessandraOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:74,000Price:--
-
Jan 08, 2024 (filed on Jan 08, 2024)Insider Name:Galbraith KennethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,706Price:$11.22
-
Jan 08, 2024 (filed on Jan 08, 2024)Insider Name:Astle ChristopherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,431Price:$11.22
-
Jan 08, 2024 (filed on Jan 08, 2024)Insider Name:Moore Paul AndrewOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,339Price:$11.22
-
Jan 05, 2024 (filed on Jan 08, 2024)Insider Name:Galbraith KennethOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Jan 05, 2024 (filed on Jan 08, 2024)Insider Name:Galbraith KennethOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
Filings by filing date
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Gallagher NeilOwnership Type:Direct OwnershipSecurities:No securities are beneficially ownedNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Gallagher NeilOwnership Type:Direct OwnershipSecurities:No securities are beneficially ownedNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Feb 08, 2024 (filed on Feb 09, 2024)Insider Name:Cesano AlessandraOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:74,000Price:--
-
Feb 09, 2024 (filed on Feb 09, 2024)Insider Name:Cesano AlessandraOwnership Type:Direct OwnershipSecurities:No securities are beneficially ownedNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Feb 09, 2024 (filed on Feb 09, 2024)Insider Name:Cesano AlessandraOwnership Type:Direct OwnershipSecurities:No securities are beneficially ownedNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 05, 2024 (filed on Jan 08, 2024)Insider Name:Galbraith KennethOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Jan 05, 2024 (filed on Jan 08, 2024)Insider Name:Galbraith KennethOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:300,000Price:--
-
Jan 05, 2024 (filed on Jan 08, 2024)Insider Name:Galbraith KennethOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-47,666Price:--
-
Jan 08, 2024 (filed on Jan 08, 2024)Insider Name:Galbraith KennethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,706Price:$11.22
-
Jan 05, 2024 (filed on Jan 08, 2024)Insider Name:Galbraith KennethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-18,198Price:$10.65
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 108 Patriot Drive, Suite A MIDDLETOWN DE 19709 |
Tel: | N/A |
Website: | https://www.zymeworks.com |
IR: | See website |
Key People | ||
Kenneth H. Galbraith Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer | Paul A. Moore Chief Scientific Officer |
Business Overview |
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251. |
Financial Overview |
For the fiscal year ended 31 December 2023, Zymeworks Inc revenues decreased 82% to $76M. Net loss totaled $118.7M vs. income of $124.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Stock-based Compensation in SGA increase from $1.2M to $5.3M (expense), Foreign exchange gain decrease from $1.2M (income) to $1.2M (expense). |
Employees: | 272 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $240.44M as of Dec 31, 2023 |
Annual revenue (TTM): | $76.01M as of Dec 31, 2023 |
EBITDA (TTM): | -$127.89M as of Dec 31, 2023 |
Net annual income (TTM): | -$118.67M as of Dec 31, 2023 |
Free cash flow (TTM): | -$122.38M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 71,219,441 as of Mar 4, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |